NASDAQ Healthcare Biotechnology TSHA

Taysha Gene Therapies, Inc.

$ 6.42 3.72 %

Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.

CEO: Sean Nolan - https://www.tayshagtx.com

Summary 30-Y Financials Dividend Analyst Key metrics Ownership / Senat
Price objectif

$12 86.92 %

Recommandation

Buy

DCF

$ 0.62

Loading data...

TSHA vs S&P500

Loading data...

No data available.

Quick ratio

14.04

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

-16.89

may indicate that the company is undervalued or has poor growth prospects.

EPS

-0.38

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

-56.07 %

indicates low profitability, suggesting that the company is not using equity efficiently to generate profits.

ROIC

-47.30 %

does not generate enough return to cover its financing costs, which indicates value destruction and may pose long-term profitability issues.

WACC

9.74

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.08

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

-0.31

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

0.00 %

the dividend payout ratio is the measure of dividends paid out to shareholders relative to the company's net income.

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
3 indicates worrying financial health
Altman score
7.03 indicates good financial health and low risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
13.76 indicates that the company has sufficient cash to cover its short-term debts
Debt Ratio
0.06 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.